News | August 18, 2022
ProBioGen enters into master service agreement with NextPoint Therapeutics
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The new program includes upstream and downstream process development and large-scale GMP production.
Susanne Kaestner joins the company as Senior Vice President, Quality and member of the Executive Team, and Dr. Thea Boehm as Vice President, Business Development.
Subscribe To Our Newsletter & Stay Updated
